tickdelta
Sign in
Screener / SEC EDGAR /CIK 0001792044 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
VRTXHSICDVALHREGNVTRS
Nasdaq Health care · Pharmaceuticals

Viatris VTRS

VTRS quote by TradingView

Viatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally. 10-K, Item 1

Headquarters
Canonsburg, PA
CEO
Scott A. Smith
Next results
around Feb 25, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2023

Revenue of $15.4B through the costs to a net profit of $54.7M · income statement of the 10-K

5% operating margin
Revenue to Gross profit: $6.4BRevenue to Cost of revenue: $9.0BGross profit to Operating profit: $766.2MGross profit to Operating expenses: $5.7BOperating profit to Net profit: $54.7MOperating profit to Tax & other: $711.5MOperating expenses to R&D: $805.2MOperating expenses to Sales, admin & other: $4.9B Revenue: $15.4B REVENUE $15.4B −5% Y/Y Gross profit: $6.4B · 42% margin GROSS PROFIT $6.4B 42% margin · −1% Y/Y Cost of revenue: $9.0B · 58% of revenue COST OF REVENUE $9.0B 58% of revenue Operating profit: $766.2M · 5% margin OPERATING PROFIT $766.2M 5% margin · −53% Y/Y Operating expenses: $5.7B · 37% of revenue OPERATING EXPENSES $5.7B 37% of revenue Net profit: $54.7M · 0% margin NET PROFIT $54.7M 0% margin · −97% Y/Y Tax & other: $711.5M · 5% of revenue TAX & OTHER $711.5M 5% of revenue R&D: $805.2M · 5% of revenue R&D $805.2M 5% of revenue Sales, admin & other: $4.9B · 32% of revenue SALES, ADMIN & OTHER $4.9B 32% of revenue
Gross profit $6.4B 42% margin · −1% Y/Y
Operating profit $766.2M 5% margin · −53% Y/Y
Net profit $54.7M 0% margin · −97% Y/Y
The full income statement, year by year

VTRS among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: -3.0%, above 2% of 59 peers (their median 7.2%) REVENUE GROWTH -3.0% · above 2% Gross margin: 35.3%, above 20% of 50 peers (their median 65.2%) GROSS MARGIN 35.3% · above 20% Operating margin: -0.0%, above 6% of 50 peers (their median 13.7%) OPERATING MARGIN -0.0% · above 6% Net margin: -4.1%, above 5% of 59 peers (their median 9.7%) NET MARGIN -4.1% · above 5% FCF margin: 14.3%, above 45% of 55 peers (their median 15.8%) FCF MARGIN 14.3% · above 45%
VTRS Peer median Below the median

What changed

18 new risk paragraphs. 10-K filed Feb 26, 2026 against Feb 27, 2025.

Risk factors
18 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Accounting checks
10 other checks clear
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
2 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

10 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 10 checks found nothing to note

  • Receivables -5.9% vs revenue -3.0% (-2.9 pts)
  • Cash from operations $2.3B vs net income −$3.5B (FY ending Dec 31, 2025)
  • Inventory +3.8% vs revenue -3.0% (+6.7 pts)
7 more checks with nothing to note
  • Same auditor in both 10-Ks: DELOITTE & TOUCHE LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

18 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.

All 18 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    As a result of the EWSR initiated in 2025, the Company has identified three strategic imperatives that will drive our future and position the Company for sustainable growth by (i) driving our base business through executing successful launches, focusing on supply chain continuity, evolving our generics portfolio over time towards more…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    With respect to the Biocon Biologics Transaction, in December 2025, Viatris entered into definitive agreements with Biocon for the sale of Viatris’ equity stake in Biocon Biologics for total consideration of $815 million, consisting of $400 million in cash and $415 million in newly issued equity shares of Biocon. The shares are subject…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    The U.S. has imposed or is considering imposing tariffs on certain imports from other countries, including pharmaceutical products, ingredients and inputs, which could significantly impact our cost of doing business. The imposition of adopted, new, announced or proposed tariffs, trade restrictions or domestic sourcing requirements on…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    Our manufacturing operations involve handling chemicals, pressurized systems, and complex equipment and electrical systems, which expose us to inherent health and safety risks. These include accidents, fires, explosions, chemical spills, and employee exposure to hazardous substances. Such incidents have in the past and could in the…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$16.3B$15.4B$14.7B$14.3B
Net income$2.1B$54.7M−$634.2M−$3.5B
Operating cash flow$3.0B$2.9B$2.3B$2.3B
Free cash flow$2.6B$2.5B$2.0B$1.9B

Revenue, FY2018 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$14.3B ▼ 3.0% in FY2025

FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

Viatris, Canonsburg, PA · from the 10-K filed Feb 26, 2026

Viatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, Viatris supplies high-quality medicines to approximately 1 billion patients around the world each year. The Company has a global footprint, an extensive portfolio of medicines that is well-diversified across therapeutic areas, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges.

Headquarters
Canonsburg, PA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 5, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VTRS/export.csv") into a cell.